Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod 5% Cream for Superficial Basal Cell Carcinoma
NCT00189306Phase 3Completed
- Sponsor
- Graceway Pharmaceuticals
- Start
- Mar 2001
- Primary completion
- Apr 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 3 trial of imiquimod in basal cell carcinoma (BCC), sponsored by Graceway Pharmaceuticals. Started Mar 2001; status: completed.
02
Drugs
imiquimod
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT00189306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189306.